Business
Avacta reports new AVA6103 pharmacology data
Avacta Group PLC announced positive new pharmacology data for its FAP-Exd (AVA6103) asset, a pre|CISION peptide drug conjugate designed for tumor-activated oncology delivery. The data demonstrate a sustained release of the exatecan payload within the tumor for over five days, with plasma exposure disappearing within two hours, leading to robust antitumor activity and more durable responses compared to conventional exatecan in patient-derived xenograft models. This second pre|CISION medicine, which utilizes an AI approach for clinical development, is anticipated to begin Phase 1 testing in Q1 2026 and has the potential to address multiple indications with high unmet need. Disclaimer*
About this update from Avacta Group Plc
[{"type":"text","content":"\n\n \nAvacta reports new pharmacology data for FAP-Exd (AVA6103)\n \nMultiple patient-derived xenograft models with prolonged complete responses associated with sustained release of the exatecan payload within the tumor over five days\n \nLONDON and PHILADELPHIA - December 18, 2025 - Avacta Therapeutics (AIM: AVCT), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated oncology delivery platform, today announced new pharmacology data with its second asset, FAP-Exd (AVA6103) which is anticipated to begin Phase 1 testing in Q1 2026. \n \nFAP-Exd (AVA6103) is a pre|CISION® peptide drug conjugate comprised of the proprietary FAP-cleavable peptide linked to a highly potent topoisomerase I (topo I) inhibitor, a key antitumor mechanism useful in many human solid tumor types. \n \nToday's new data include the following observations:\n \n· Potent tumor-specific and broad-spectrum cytotoxicity: FAP-Exd (pre|CISION exatecan) is a potent peptide drug conjugate designed to produce sustained release of active exatecan directly in the tumor via the pre|CISION bystander effect\n \n· Sustained release mechanism in the tumor is highly effective: The sustained release mechanism produces a maximum concentration (Cmax) of released exatecan, with exposure duration of over five days in the tumor, with plasma exposure gone in two hours\n \n· High levels of antitumor activity of FAP-Exd: Multiple patient-derived xenograft models demonstrate robust antitumor activity with deeper and more durable responses than achieved with conventional exatecan\n \n· FAP-Exd has the potential to reach a broad patient population with high unmet need: Exatecan is the most potent topoisomerase I inhibitor that has been tested in the clinic and as a pre|CISION medicine delivers exatecan directly to the tumor with the potential to address multiple indications with high unmet need\n \n· Faster and more robust Phase 1 development using AI: The clinical development of FAP-Exd was designed using an AI approach, querying a large database to identify those cancer indications with the highest likelihood of response to the drug through co-expression of FAP and SLFN11\n \n \n \nChrist...